Yes, dispensing fee; thank you, former health minister Priddy.
So they actually pay them a double fee—in the last year, that amounted to some $750,000—for not prescribing when there was evidence that the prescription could harm the patient, could be ineffective, or could conflict with other medications they were taking. In the rush to bring in new drugs, although it's great that they may be very innovative, we want to make sure that we're not in fact contributing to other costs when drugs fail if they're not adequately scrutinized before they come in.
What in fact is your industry doing to strengthen evidence of safety and effectiveness of therapies over the life cycle of the products?